(Updates)
** Shares of drug developer Keros Therapeutics fall ~77% to its lowest level of $15.96 since its Nasdaq debut in April 2020
** KROS says it has halted dosing of 3.0 mg per kg and 4.5 mg per kg doses of its high blood pressure treatment in a mid-stage study due to fluid buildup around the heart
** Dosing in the 1.5 mg/kg arm will continue after a risk-benefit review by an independent monitoring committee - KROS
** Co has notified the U.S. FDA about it and expects to present data from all treatment arms in Q2 2025 - KROS
** Including session's moves, stock has fallen 58.6% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。